TWMP
BMRN icon

Taylor Wealth Management Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Taylor Wealth Management Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,837
Closed -$748K – 65
2020
Q3 		$748K Sell
9,837
-15,476
-61% -$1.57M 0.34% 42
2020
Q2 		$3.12M Buy
+25,313
New +$2.52M 1.59% 23

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Taylor Wealth Management Partners's BMRN Position: Q4 2020 in Review

Taylor Wealth Management Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 9,837 shares — an estimated $748K sold.

Taylor Wealth Management Partners first reported a position in BMRN in Q2 2020 and held it in 2 quarters. The position peaked at $3.12M in Q2 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Taylor Wealth Management Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Taylor Wealth Management Partners sold 9,837 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $748K.
  • Taylor Wealth Management Partners first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Taylor Wealth Management Partners's BioMarin Pharmaceuticals position peaked at $3.12M in Q2 2020.
  • 537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Taylor Wealth Management Partners's 13F filing for Q4 2020, filed 2 Feb 2021.